Mark Hensley

Mark Hensley is the Chief Executive Officer at Veloxis Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to enhancing the lives of transplant patients. Prior to this role, Mark held various executive positions at companies like Xenikos B.V., Chiesi USA, Inc., and Cornerstone Therapeutics. Mark has a Bachelor of Science degree in Biology with a minor in Chemistry from the University of North Texas.